Sight Sciences (NASDAQ:SGHT) Insider Sells $48,851.55 in Stock

Key Points

• Insider sale: Jeremy Hayden sold 13,761 shares at an average price of $3.55 on April 6 for $48,851.55, reducing his stake by 3.59% to 369,770 shares; the trade was executed under a pre-arranged Rule 10b5-1 plan.
• Stock and outlook: SGHT traded around $3.50 (up 0.6%), has a market cap of about $189M and a negative PE, a 12‑month range of $2.14–$9.24, and carries a consensus analyst rating of Hold with an average target of $8.31.

Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) insider Jeremy Hayden sold 13,761 shares of the company's stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $3.55, for a total value of $48,851.55. Following the completion of the sale, the insider directly owned 369,770 shares of the company's stock, valued at approximately $1,312,683.50. This trade represents a 3.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sight Sciences Trading Up 0.6%

Shares of SGHT stock traded up $0.02 on Thursday, reaching $3.50. The company had a trading volume of 115,412 shares, compared to its average volume of 312,645. The company has a current ratio of 10.22, a quick ratio of 9.52 and a debt-to-equity ratio of 0.63. The company has a 50-day moving average of $4.67 and a 200-day moving average of $5.74. Sight Sciences, Inc. has a 12 month low of $2.14 and a 12 month high of $9.24. The stock has a market cap of $189.02 million, a PE ratio of -4.67 and a beta of 2.50.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last issued its quarterly earnings data on Wednesday, March 4th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.07. Sight Sciences had a negative return on equity of 55.72% and a negative net margin of 49.67%.The business had revenue of $20.39 million during the quarter, compared to analyst estimates of $20.35 million. On average, equities analysts forecast that Sight Sciences, Inc. will post -0.99 earnings per share for the current year.

Hedge Funds Weigh In On Sight Sciences

A number of large investors have recently bought and sold shares of the company. Long Focus Capital Management LLC boosted its position in Sight Sciences by 1.3% during the 3rd quarter. Long Focus Capital Management LLC now owns 3,193,305 shares of the company's stock worth $10,985,000 after acquiring an additional 41,797 shares during the last quarter. Vanguard Group Inc. boosted its position in Sight Sciences by 5.7% during the 3rd quarter. Vanguard Group Inc. now owns 1,906,696 shares of the company's stock worth $6,559,000 after acquiring an additional 102,609 shares during the last quarter. Americana Partners LLC boosted its position in Sight Sciences by 12.1% during the 4th quarter. Americana Partners LLC now owns 1,378,980 shares of the company's stock worth $10,935,000 after acquiring an additional 149,161 shares during the last quarter. Geode Capital Management LLC boosted its position in Sight Sciences by 3.3% during the 4th quarter. Geode Capital Management LLC now owns 880,958 shares of the company's stock worth $6,988,000 after acquiring an additional 27,802 shares during the last quarter. Finally, State Street Corp boosted its position in Sight Sciences by 11.0% during the 4th quarter. State Street Corp now owns 737,359 shares of the company's stock worth $5,847,000 after acquiring an additional 73,362 shares during the last quarter. Institutional investors and hedge funds own 55.51% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Cantor Fitzgerald set a $8.00 price objective on Sight Sciences in a research report on Monday, March 2nd. UBS Group decreased their price objective on Sight Sciences from $12.00 to $11.00 and set a "buy" rating for the company in a research report on Friday, March 6th. Piper Sandler set a $9.00 price objective on Sight Sciences in a research report on Monday, January 5th. William Blair reiterated an "outperform" rating on shares of Sight Sciences in a research report on Thursday, March 5th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of Sight Sciences in a research report on Monday, December 29th. Five analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Sight Sciences has a consensus rating of "Hold" and an average target price of $8.31.

Sight Sciences Company Profile

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company's flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye's natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.